Splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes is an indolent lymphoma that typically affects elderly patients. Treatment is required in symptomatic cases. Splenectomy remains one of the first-line options in patients fit for surgery. The best therapeutic strategy has not yet been identified. Among different possible chemotherapeutic approaches, purine analogues, alone or in association with rituximab, seem to be a valid therapeutic choice.
Section of Hematology, Department of Oncology, Transplants and Advances in Medicine, University of Pisa, Ospedale S. Chiara, Via Roma 56, Pisa, Italy. juliacervetti@alice.it
